Finerenone, polypharmacy, and clinical outcomes in heart failure: pre-specified analysis from the FINEARTS-HF trial - PubMed
5 hours ago
- #Heart Failure
- #Polypharmacy
- #Finerenone
- Finerenone's efficacy and safety were evaluated in HFmrEF/HFpEF patients with varying levels of polypharmacy.
- Over 90% of participants met polypharmacy or hyper-polypharmacy criteria, with higher medication counts linked to increased cardiovascular event risks.
- Finerenone consistently reduced cardiovascular death and HF events across all medication categories without increasing adverse events or discontinuation rates.
- The study highlights the safety and benefits of finerenone in patients with high comorbidity burdens requiring multiple medications.